SOAT1 and rheumatoid arthritis: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor that modulates the JAK–STAT signaling pathway, which plays a central role in the pathogenesis of several inflammatory diseases, including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and atopic dermatitis (AD) [1].